GVBP closed with a gain of over 17% today.

GVBP traded an amazing 39 million shares in volume!

We alerted our members on GVBP 2 days ago and it is now up over 40% since our alert!

I believe the momentum on GVBP could continue in the next few days!

GVBP is the type of stock that could be a Life-time opportunity!

GVBP also released a HUGE PR today.

GVBP believes they could reach up to 400 million dollar in revenue per annum given their drugs are successfully developed!

As we mentioned in the past, GVBP has a CEO who has ties with Glaxo Smith Kline! One of the biggest drug companies in the world.

GVBP also stated that they were working on a DAILY BASIS to close Licensing Agreement with Big Pharma Companies. If successful, GVBP could move higher!

HGSI another Bio stock recently went from about 50 cents to over $19.00 !

That is a gain of over 2000%!

CTIC another bio deal moved from 5 cents to over $1.50!

A gain of over 1000%!

I believe GVBP could be the next Bio Stock to go insane!

GVBP is performing well so far and I think the best has yet to come. Especially after today`s PR, I believe we could see more news from the Company!

** At 18 cents, GVBP could be a HUGE BARGAIN! **

http://genovabio.com

About GVBP

GENova (OTCBB: GVBP) is a biotechnology drug development company focused on the development and commercial licensure of new drug targets for treatment and prevention of cancers and other infectious diseases. The Company, through its extensive global network and expertise in evaluating projects/IP, identifies and validates promising early-stage, or already patented discovery projects. These drugs target disease indications with significant unmet needs, and have substantial market potential.

Bio stocks are among the most profitable stocks in the market. Those types of stocks can move up on rumours but also skyrocket on material announcements.

As mentioned previously, perfect examples of Bio Stocks that recently went through the roof include:

HGSI +2000%, CTIC +1500%, VNDA +1000%!

GVBP could be the next Multi-Bagger!

If you look at the chart below, you will see that GVBP is showing a very bullish sign and could break out very soon!

In fact, I wouldn’t be surprise to see GVBP move higher in the next few days!

GVBP chart: http://www.profitspi.com/stock-chart.aspx?id=GVBP&ca=1445319399

** GVBP Could reach 400 Million dollar in revenue per year! **

GVBP released a HUGE PR today. The Company believes that their revenue could hit 400 million dollar per year if they successfully implement their drugs!

That is a very positive announcement since it shows how confident the Company believes in their products and its revenue potential!

GVBP could be the next micro-cap stock to soar under strong fundamentals!

I believe the volume today we saw on the stock is a good bullish indicator!

I believe there is a strong accumulation on GVBP for a potential Move NORTH!

Link to the PR:

http://finance.yahoo.com/news/GENova-discusses-development-prnews-833114775.html?x=0&.v=1

The PR also stated the following:

Big Pharma presently has $215 Billion to spend on licensing of new drugs, and is eager to feed the pipeline for new anti-cancer drugs, as cancer represents the largest disease market, and has an explosive growth rate of 20% per annum. Of the types of cancer, prostate cancer represents the largest market and breast cancer the second.

This is a PERFECT opportunity for GVBP since their products focus on Prostate and Breast Cancer!

If GVBP develop efficient products they could become a perfect take over candidate for big pharmaceutical companies like Pfizer, Amgen or Glaxo Smith Kline!

**Why we Love GVBP! **

We already mentioned several reasons in the past why we LOVE GVBP. Here`s a quick recap:

- GVBP has a VERY STRONG management team who worked with big Pharma Company like Glaxo Smith Kline and Bayer!

- GVBP believes that licensing fees from their products could rise to 700 million dollar!

- The market for Therapeutic cancer is expected to grow to over 11 Billion dollar by 2011!

- GVBP released over 3 PRs in the last week! GVBP is on a PR roll that could continue!

- GVBP has very bullish technical indicators that fuel the momentum even more!

**The Techinical Indicators on GVBP points North! **

GVBP has positive technical indicators that could translate in a move higher very soon:

- The volume is enormous! GVBP traded close to 80 million shares in the last couple of days! Volume is usually a good indicator of strong accumulation and interest in a stock!

- GVBP closed GREEN 3 days in a row! This means that GVBP could continue running tomorrow!

- GVBP has a very positive money flow! This means that a huge amount of capital is being infused in the stock. This is a strong accumulation sign for a potential move North!

The trend is your friend! GVBP could be the ride of a life time!

GVBP is still our FAVORITE PICK !

Make sure you keep an eye on GVBP. We believe the BEST has yet to come!

MonsterStox.com Team

**********************
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. We might buy or sell this security without notice. Always do your own due diligence before investing in any stock mentioned in this newsletter. The disclaimer is to be read and fully understood before using our site, or joining our email list.

PLEASE NOTE WELL: The MonsterStox.com employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at:

http://www.MonsterStox.com/Disclaimer.html

Release of Liability: MonsterStox.com is wholly owned and operated by Golden Dragon Media Inc. Through use of this website viewing or using you agree to hold MonsterStox,.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not puport to be a complete statement or summary of the available data. The third party may have shares and may liquidate it, which may negatively affect the stock price. Monsterstox.com received ten thousand dollar for a one month profile of GVBP from a Third Party. We are currently negotiating for more compensation on GVBP. When received and confirmed we will disclose it.This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. MonsterStox.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. MonsterStox.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. MonsterStox.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. MonsterStox.com, nor any of its affiliates are not registered investment advisors or a broker dealers.

The Bad News

The stock’s decline to $3.45 from $20 at the beginning of September is a consequence of several factors, in our opinion, none of which include failure to execute. First, the broader markets have pulled back over the same period considerably. The Nasdaq has traded down about 1,100 points, or 45% over this period. Second, rumors have been widespread that a major holder of APWR, a fund, has been liquidating stock. Whether or not this is true or not does not impact the “perception” on the Street that more weakness is on tap, so the stock has failed to get any real support. Third, the company terminated its CFO due to some incompetence administratively. There was no fraud. But the CFO was holding multiple jobs and was forced to resign. Fourth, the company is a Chinese company. Regardless of the fact that U.S. companies have proven lately there is no reason to believe they are any more credible than anyone else, the fact that APWR operates in China, and its management is not exactly friendly to clear and open communication in the English tongue, its credibility is lessened, and again, this undermines support for the stock.

The Good News

OK – so that is the bad news, and the catalysts, in our opinion, for the weakness in the stock. The good news is that we see this as a pretty unique opportunity to buy a tremendous growth stock of a company poised for long-term aggressive growth below book value. Here are the reasons we are buyers of the stock:

· Diversified Business Model And Huge Addressable Markets – APWR operates two primary businesses: distributed energy and wind power, both targeted to the Asian markets.

The problems with traditional central power generation in China is that it is inefficient, dirty, the cost of maintenance is high, there are issues with power due to transportation over longer distances, there are frequent blackouts and the overall cost of power, driven by supply and demand economics, is high.

APWR ’s approach is to develop and market factory byproducts, or excess steam, to create cheap, on-site power and free heat. It offers customers greater than 80% efficiency as opposed to the 20% to 40% offered by traditional power. The excess power generated can be sold to local users via a micro grid or over the national grid. From a cost standpoint, APWR can offer power at one-third to one-fifth of the cost as national grid power and the system plowback for customers is 2 to 5 years.

Management said last week that in the Q3 it secured a new distributed generation contract in China worth about $195 million, and it signed a binding MOU with National Power Supply Company for $300 million to develop a 600MW distributed power system in Thailand. Its current backlog for distributed generation is more than $800 million.

There is huge market potential for APWR , given that the PRC government estimates that spending on power generation in China will be at least $65 to $78 billion annually for the next four years. APWR has the opportunity to capture its share of this spend.

On the wind power development side, APWR is poised to become a market leader in China’s burgeoning market. One of the most compelling points about APWR ’s entrance into this business is that it didn’t need to raise money to enter the China wind market. Its cash flow has been sufficient to fund expansion.

It has established a technology advantage in the market by entering into licensing agreements for leading European wind turbine technology with Fuhrlander to produce and sell its turbines in China. APWR has been in the process of negotiating an LOI for 380 turbines, which price about $3 to $4 million each. So far it has concluded contracts for 50 of this total, representing about $150 to $200 million in backlog on the wind business.

China’s wind energy market is huge. About 2.2GW, or less than 1% of China’s total energy production in 2006 was from wind. The Chinese government recently announced plans to ramp wind energy production to 100GW by 2020 (15% of China’s projected 2020 energy output). APWR has the rights to build up to seven wind farms in key locations as well, where the combined capacity is more than 2GW.

· Proven Ability to Execute. The markets are totally discounting the fact that APWR has demonstrated an ability to execute its model. In 2006, it generated $98 million in revenue and $7.6 million in income. In 2007 it generated $152 million in revenue and $16.7 million in income. This year it is forecasting $35 million in income and next year it is guiding to $70 million in income.

· Valuation is Compelling. The stock is trading about 2x its cash per share, less than 1x book value, 3.2x this year’s earnings and 1.6x next year’s income. It is trading at .11x its backlog. At a mere 5x next year’s income, the stock would be trading at $10.70, a 210% from current levels.

Our bottom line is that the stock is tremendously oversold, and in no way reflects the execution of the business, nor the opportunity. To be sure, the markets are going to continue to be volatile, and we expect broader market weakness for the foreseeable future, which may create pressure on APWR’s stock. That being said, we think the markets will be stabilizing this time next year, looking forward to 2010. At which point, valuations will likely move back to historically ‘normal levels.’

The average estimate for the S&P has traditionally been about 14x income. At 14x projected 2009 income, APWR would be trading at $29, assuming its hits its guidance of $70 million. So again, we see tremendous upside in this stock.

Here is what the analysts are saying:

· Dougherty & Company – rates APWR a BUY with a $10 price target

· Roth Capital – rates APWR a HOLD with a $10 price target

· Jesup & Lamont – rates APWR a BUY with a $19 price target

· Wedbush Morgan – rates APWR a HOLD with a $13 price target

Important Disclosure: SCPEditor is LONG APWR. The information and trades provided here and in the comments are for informational purposes only and are not a solicitation to buy or sell any of these securities. Investing involves substantial risk and you should evaluate your own risk levels before you make any investment. Past results are not an indication of future performance.